Genetic interactions in the β-adrenoceptor/G-protein signal transduction pathway and survival after coronary artery bypass grafting: a pilot study.
暂无分享,去创建一个
G Heusch | U. Frey | I. Manthey | W. Siffert | G. Heusch | K. Leineweber | J. Peters | E. Kottenberg | J Peters | U H Frey | E Kottenberg | M Kamler | K Leineweber | I Manthey | W Siffert | M. Kamler
[1] E. Peterson,et al. Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. , 2002, JAMA.
[2] S. Vatner,et al. Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(salpha) mouse. , 1999, The Journal of clinical investigation.
[3] R. Kim,et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. , 2001, The New England journal of medicine.
[4] S. Vatner,et al. β-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsα mouse , 1999 .
[5] I. Zineh,et al. Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. , 2007, The American journal of cardiology.
[6] S. Humphries,et al. Role of β adrenergic receptor polymorphisms in heart failure: Systematic review and meta‐analysis , 2008, European journal of heart failure.
[7] Julie A. Johnson,et al. Pharmacogenetics of beta-blockers. , 2007, Pharmacotherapy.
[8] Martin J. Lohse,et al. β2-Adrenergic Receptor Redistribution in Heart Failure Changes cAMP Compartmentation , 2010, Science.
[9] M. McCaul,et al. Differential expression of guanosine triphosphate binding proteins in men at high and low risk for the future development of alcoholism. , 1994, The Journal of clinical investigation.
[10] O. Brodde. β1‐ and β2‐Adrenoceptor polymorphisms and cardiovascular diseases , 2008 .
[11] S. Vatner,et al. Adverse Effects of Chronic Endogenous Sympathetic Drive Induced by Cardiac Gsα Overexpression , 1996 .
[12] W. Kraus,et al. Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. , 2008, Journal of the American College of Cardiology.
[13] E. Peterson,et al. Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. , 2002, JAMA.
[14] R. Schmieder,et al. A novel-1364A/C aquaporin 5 gene promoter polymorphism influences the responses to salt loading of the renin-angiotensin-aldosterone system and of blood pressure in young healthy men , 2008, Basic Research in Cardiology.
[15] U. Frey,et al. PCR-amplification of GC-rich regions: 'slowdown PCR' , 2008, Nature Protocols.
[16] S. Vatner,et al. Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression. , 1996, Circulation research.
[17] K. Santos,et al. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. , 2008, The American journal of cardiology.
[18] Y. Ishikawa,et al. Overexpression of Gs alpha protein in the hearts of transgenic mice. , 1995, The Journal of clinical investigation.
[19] S. Vatner,et al. Cardiomyopathy induced by cardiac Gs alpha overexpression. , 1997, The American journal of physiology.
[20] Julie A. Johnson,et al. Pharmacogenetics of β‐Blockers , 2007 .
[21] M. Ergun,et al. Association of β‐1 and β‐2 adrenergic receptor gene polymorphisms with myocardial infarction , 2009, Journal of clinical laboratory analysis.
[22] U. Frey,et al. A novel functional haplotype in the human GNAS gene alters Galphas expression, responsiveness to beta-adrenoceptor stimulation, and peri-operative cardiac performance. , 2009, European heart journal.
[23] J. Blouin,et al. &bgr;2-Adrenoceptor Genotype Affects Vasopressor Requirements during Spinal Anesthesia for Cesarean Delivery , 2006 .
[24] J. Seidman,et al. Natriuretic Peptide System Gene Variants Are Associated with Ventricular Dysfunction after Coronary Artery Bypass Grafting , 2009, Anesthesiology.
[25] P. McCullagh,et al. Some aspects of analysis of covariance. , 1982, Biometrics.
[26] C. Londos,et al. A highly sensitive adenylate cyclase assay. , 1974, Analytical biochemistry.
[27] G. Heusch,et al. β1‐ and β2‐Adrenoceptor polymorphisms and cardiovascular diseases , 2009 .
[28] P. Ghahramani,et al. Influence of genetic polymorphisms in the β2-adrenoceptor on desensitization in human lung mast cells , 2000 .
[29] K. Jöckel,et al. A novel promoter polymorphism in the human gene GNAS affects binding of transcription factor upstream stimulatory factor 1, G&agr;s protein expression and body weight regulation , 2008, Pharmacogenetics and genomics.
[30] J. Spertus,et al. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. , 2005, JAMA.
[31] T. Lumley,et al. &bgr;2-Adrenergic Receptor Polymorphisms and Risk of Incident Cardiovascular Events in the Elderly , 2003, Circulation.
[32] I. Zineh,et al. Relation of β2-Adrenoceptor Haplotype to Risk of Death and Heart Transplantation in Patients With Heart Failure , 2007 .
[33] J. Spertus,et al. β2-Adrenergic Receptor Genotype and Survival AmongPatients Receiving β-Blocker Therapy After an Acute Coronary Syndrome , 2005 .
[34] O. Brodde. Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. , 1991, Pharmacological reviews.
[35] H. Hense,et al. Characterization of the GNAQ promoter and association of increased Gq expression with cardiac hypertrophy in humans. , 2008, European heart journal.
[36] Paul Bentley,et al. Down but not out: candidate gene-based studies still have value in a world dominated by whole genome approaches. , 2010, Circulation research.
[37] Jaekyu Shin Pharm.D. and. Pharmacogenetics of β-Blockers , 2012 .
[38] H. Völzke,et al. Angiotensin I-converting enzyme insertion/deletion polymorphism and cardiac mortality and morbidity after coronary artery bypass graft surgery. , 2002, Chest.
[39] S. Vatner,et al. Overexpression of myocardial Gsalpha prevents full expression of catecholamine desensitization despite increased beta-adrenergic receptor kinase. , 1998, The Journal of clinical investigation.
[40] M. Packer,et al. Neurohormonal interactions and adaptations in congestive heart failure. , 1988, Circulation.
[41] J. Blouin,et al. beta2-adrenoceptor genotype affects vasopressor requirements during spinal anesthesia for cesarean delivery. , 2006, Anesthesiology.
[42] P. Amouyel,et al. The impact of beta‐adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure * , 2005, European journal of heart failure.